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Abstract
Several SNPs located in or around the IL28B gene are associated with response of patients infected with Hepatitis C virus to
treatment with pegylated interferon-a +/2 ribavirin or with spontaneous clearance of the virus. The results of such studies
are so compelling that future treatment approaches are likely to involve clinical decisions being made on the basis of a
patient’s genotype. Since IL28B is a paralogue of IL28A with greater than 95% sequence identity, it is possible that without
genotyping assay specificity, sequences in IL28A may contribute to genotype identification, and potentially confound
treatment decisions. This study aimed to 1) examine DNA sequences in IL28B surrounding each of the reported associated
SNPs and the corresponding regions in IL28A; and 2) develop a robust assay for rs12979860, the most ‘cosmopolitan’ SNP
most strongly associated with treatment response across all global populations studied to date. Bioinformatic analysis of
genomic regions surrounding IL28A and IL28B demonstrated that 3 SNPs were unique to IL28B, whereas the remaining 6
SNP regions shared .93% identity between IL28A and IL28B. Using a panel of DNA samples, PCR amplification followed by
Sanger sequencing was used to examine IL28B SNPs and the corresponding regions in IL28A. For the overlapping SNPs, all 6
in IL28B were confirmed to be polymorphic whereas the corresponding positions in IL28A were monomorphic. Based upon
IL28A and IL28B sequence data, a specific TaqManH assay was developed for SNP rs12979860 that was 100% concordant to
the sequence-derived genotypes. Analysis using a commercial assay identified one discordant result which led to a change
in their genotype-calling algorithm. Where future treatment decisions are made upon the results of genotyping assays, it is
very important that results are concordant with data from a sequence-based format. This is especially so in situations where
designing specific PCR primers is a challenge.
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Introduction
Worldwide there are over 170 million individuals who are
chronically infected with Hepatitis C virus (HCV) [1]. Frontline
therapy is currently pegylated interferon-a either alone or in
combination with ribavirin, although new direct-acting antiviral
treatments (boceprevir and telaprevir) [2,3] have recently received
FDA approval. It was known that sustained virological response
(SVR) rates following interferon treatment varied amongst
individuals and across different populations suggesting that a
genetic component contributed to treatment response. In late 2009
genetic evidence supporting this was identified through the use of
genome-wide association studies. Several single nucleotide poly-
morphisms (SNPs) located in and around the IL28B gene were
found to be associated with treatment response in patients
chronically infected with HCV [4–6]. In total, these papers
identified 9 SNPs that were either associated with increased SVR
or with a null virological response (NVR). In addition, some of
these SNPs were also associated with spontaneous clearance of
HCV [7]. Since these original studies, there have now been
hundreds of papers examining genotype associations with some of
these 9 SNPs. In addition, HCV treatment algorithms that include
patient genotype are now being considered [8,9].
IL28B lies in close proximity on chromosome 19 to its paralogue
IL28A, a gene with which it shares .95% sequence identity [10].
This high level of sequence identity between the 2 genes raised a
potential concern that sequences within IL28A may interfere with
genotype determination unless a robust, validated genotyping
assay was developed. To address this potential concern, this study
sought to carry out a detailed bioinformatic analysis of the regions
surrounding the IL28A and IL28B gene duplication and to
genotype a number of samples by sequencing the DNA
surrounding the SNPs in IL28B as well as the corresponding
region of IL28A. Finally, a specific and robust genotyping assay
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A 43 kb fragment of chromosome 19 encompassing the
sequences of IL28A and IL28B (corresponding to nucleotides
39,727,000–39,770,000 from NCBI Genome Build 37) was
extracted and subjected to bioinformatic analysis using Clustal
W [11]. Since IL28A and IL28B are found on the forward and
reverse strands, respectively, an alignment comparing the
extracted sequence to the reverse complement of the same
sequence was performed. The locations of each of the SNPs
rs8105790, rs11881222, rs8103142, rs28416813, rs4803219,
rs12979860, rs12980275, rs8099917 and rs7248668 were identi-
fied on the resulting alignment.
Sequence analysis
A panel of 48 genomic DNA samples was obtained from the
Coriell Institute (Camden, NJ). These comprised 16 samples each
from individuals of Caucasian (CEU), Japanese (JPT) and Yoruba
(YRI) origins. PCR amplification of 8 regions spanning the 9 SNP
locations and the corresponding regions of IL28A was performed
using the HotStarTaq PCR kit (Qiagen, Germantown, MD). The
PCR reactions (25 uL) included 25 ng of DNA and amplifying
primers at a final concentration of 0.4 mM. After enzyme
activation at 95uC for 15 minutes, there were 35 PCR cycles
comprising 1 minute denaturation at 94uC, 1 minute at the
appropriate annealing temperature and 3 minutes extension at
72uC. The last cycle was followed by a final extension at 72uC for
10 minutes. Some amplicons required the use of Q-Solution
(Qiagen) as 20% of the reaction volume for amplification.
Fragment sizes ranged from 476–2500 bp (Table 1).
Primers were designed for specificity to either IL28A or IL28B
by choosing primer annealing sites with the greatest number of
mismatches between the two genes. To further avoid mispriming
from homologous regions, the annealing temperature was
determined empirically for each set of primers using a gradient
cycle from 50uCt o6 8 uC on test samples prior to amplifying from
the 48 DNA sample panel. In all cases, the highest annealing
temperature that produced a single robust band on a gel and
specific IL28A or IL28B sequence data was used for subsequent
amplification from the complete panel (Table 1).
Five PCR fragments spanned regions in the IL28B gene and 3
fragments covered the corresponding regions of IL28A. Purifica-
tion and direct Sanger sequencing of the products was performed
by Beckman Coulter Genomics (Morrisville, NC). All products
were sequenced either using their amplification primers or using
additional internal sequencing primers (see Table S1). The
resulting data was assembled and analysed using Sequencher 4.7
(Gene Codes Corporation, Ann Arbor, MI). Representative
sequence traces for each of the SNP locations and genotypes are
given in the Figure S1.
TaqManH genotyping assay
A specific TaqManH genotyping assay was developed for
rs12979860 using Qiagen’s Type- itH Fast SNP Probe PCR
chemistry. Primer and probe oligonucleotides were designed
following as closely as possible to the default parameters of Primer
Express 3.0 (Applied Biosystems Inc., Foster City, CA), however,
in order to choose primers that annealed to specific locations in
IL28B, some exceptions were made (such as product size,
nucleotide runs and Tm). Primers amplifying a 214 bp product
that was specific to IL28B (Table 2) were manufactured by Applied
Table 1. Details of PCR amplicons used to examine SNP locations in IL28B and the corresponding reverse complement (RC)
regions of IL28A.
Target Gene Fragment Size (bp) SNPs covered Amplifying Primer Sequences Annealing Temp. (6C) 20% Q Solution
IL28B 1697 rs12980275 59 AGCAAGAGGAGGGAAGGAAG 39 64 No
rs8105790 59 CCCTGGATAAGCCCCTACAG 39
IL28B 1115 rs11881222 59 TGGGTGTCTTTTCCTCATTG 39 58 No
rs8103142 59 CCTCCAATCCCATCAGAG 39
IL28B 919 rs28416813 59 TGACCCTTGGAGTGCGGG 39 60 Yes
rs4803219 59 ATATGCCAGGAGTGGTGG 39
IL28B 593 rs12979860 59 CCAGCAGCTCCAGGATCG 39 58 Yes
59 GCAGGCGCCTCTCCTATG 39
IL28B 1291 rs8099917 59 TCACCATCCTCCTCTCATCC 39 64 No
rs7248668 59 GCACCCAAAGCCTAACCATA 39
IL28A 476 RC of rs12979860 59 ACACACCCGTCGCTGACC 39 60 Yes
59 CTCTCCCGTCCGCTTCTG 39
IL28A 2500 RC of rs11881222 59 GCCAATTGGTGAACTGTCAT 39 60 No
RC of rs8103142 59 CCCAGCTCATCAAGTGTGTCT 39
RC of rs28416813
RC of rs4803219
IL28A 990 RC of rs8105790 59 CCACAAATGAGGGGGACA 39 60 No
59 TGGCCAGCTGGTTCTTCTAC 39
doi:10.1371/journal.pone.0029983.t001
IL28 Polymorphism Sequencing and rs12979860 Assay
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thermal cycler (Applied Biosystems Inc.) using 10 ng DNA as the
template. Enzyme activation and the initial denaturation cycle was
at 95uC for 5 minutes, followed by 40 cycles of 95uC for
15 seconds and 60uC for 1 minute. Plates were read on an ABI
7900HT (Applied Biosystems Inc.) and the data was analyzed
using SDS 2.3 software (Applied Biosystems Inc.).
Comparison to a commercial rs12979860 assay
A subset of 24 of the 48 genomic DNA samples that had been
sequenced and genotyped were selected for rs12979860 SNP
analysis by Monogram Bioscience Inc. (San Francisco, CA). Nine
samples were selected to represent the CC genotype, 8 samples to
represent CT genotype and 7 samples to represent TT genotype.
Aliquot parts of the same DNA samples that had been sequenced
and genotyped were submitted for analysis. No details of the
testing procedure or analytical validity of the LabCorp Inc. assay
have been published [12].
Results
Bioinformatics
Analysis of the IL28 gene region confirmed 97.5% sequence
identity between the coding exons and introns of the IL28A and
IL28B genes. In addition, the analysis also showed that a 7.3 kb
region extending both upstream and downstream of the two genes
shared greater than 95% sequence identity (illustrated in Figure 1).
Six of the 9 reported SNPs associated with pegylated interferon
treatment response in HCV patients were located within this
7.3 kb block and each of these SNPs matched regions present in
the DNA sequence surrounding IL28A (Figure 2). Interestingly,
one of the 2 alleles across each 6 SNP locations in the IL28B
reference sequence (NCBI Genome Build 37) exactly matched the
corresponding position in IL28A and the ancestral allele. For
example, for rs12979860 the two alleles reported for this SNP
were C and T. The reference nucleotide at this location in IL28B
was C, whereas it was a T in the reverse complement of IL28A
and the ancestral allele was also a T. This finding, together with
the high levels of sequence identity across the 7.3 kb region, raised
theoretical questions about the potential specificity of genotyping
assays for 6 of the 9 reported SNPs. To address this matter, a PCR
amplification and Sanger sequencing approach was taken to
obtain definitive DNA sequence data to confirm the presence of
SNPs in IL28B and to enable assay development for the most
cosmopolitan SNP, rs12979860.
Sequence analysis
For each of 48 different DNA samples, 8 regions spanning SNPs
within and surrounding IL28B, as well as the corresponding
regions of IL28A, were amplified by PCR and the resulting
products were sequenced directly using BigDyeH terminator
chemistry (Applied Biosystems Inc.). Sequences were assembled
to provide a consensus sequence for each PCR fragment and the
alleles at each SNP location identified. All 9 SNPs previously
identified that were associated with pegylated interferon treatment
response were found to be polymorphic, whereas the 6
overlapping regions in IL28A were all monomorphic (Tables 3
and 4). Allele frequencies for the CEU, JPT and YRI populations
were similar to those reported in dbSNP.
By carrying out a sequence-based analysis of PCR fragments
spanning the IL28A and IL28B loci, a total of 17 novel SNPs were
also identified across the 48 samples; one was present in IL28A and
the remaining 16 were in IL28B. Of these 17 SNPs, all were present
in non-coding regions except for one, E95Q, that was present in an
IL28B protein-coding exon. The novel SNPs were all confirmed in
double stranded sequence. Each SNP was a heterozygote and they
were only present in one or two individual samples (Table S2).
Assay for rs12979860
rs12979860 has become the most widely studied SNP in the
HCV field since the original publications reporting the results of
Table 2. TaqManH amplification primers and detection
probes for the rs12979860 genotyping assay.





Nucleotides that gave the amplifying primers their specificity for IL28B are
shown in bold underlined. The SNP location in the probes is indicated by the
underlined nucleotide in larger font.
doi:10.1371/journal.pone.0029983.t002
Figure 1. Schematic showing IL28 genes, SNP locations and areas of sequence homology. Illustration of the relative locations of the IL28A
and IL28B genes on the forward and reverse DNA strands on chromosome 19. The shaded boxes indicate regions of the inverted duplication with
.95% sequence identity. The direction of the shaded gradient indicates the orientation of the match. SNP identifiers in blue were unique to the IL28B
region, whereas SNPs highlighted in other colors were present in the IL28B region as well as a corresponding region in IL28A.
doi:10.1371/journal.pone.0029983.g001
IL28 Polymorphism Sequencing and rs12979860 Assay
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sequence of the fragment containing this SNP, a sensitive
TaqManH based assay was developed. The specificity of the assay
was driven by the amplification primers (Figure 3). Specifically, the
forward primer had 4 base mismatches compared to IL28A,
including the final base at the terminal 39 end, and the reverse
primer had 3 base mismatches. Although the VIC-labeled probe
sequence was common to both IL28A and IL28B, the specific
amplification of IL28B allowed for gene-specific discrimination as
illustrated in Figure 4.
The TaqManH assay gave results that were 100% concordant
with the sequence based data using the 48 DNA samples
previously examined. To determine the lower confidence limits
of the concordance, a Beta distribution was used. The distribution
of underlying true probabilities generating ‘s’ successes in ‘n’ trials
is given by Beta(p, s+1, n–s+1), and this was used to determine that
the underlying 99% and 95% lower confidence limits on
concordance were 91.03% and 94.07%, respectively.
The genotype results of all 48 Coriell Institute DNA samples are
listed in the Table S3), alongside sequence traces used to make the
rs12979860 genotype calls (Figure S2).
Comparison with other data sources
HapMap data for rs12979860 was available for the JPT and
YRI samples (Table S3). Genotypes for 30 of 32 samples were
100% concordant, with no data available for two samples. In
addition, a subset of 24 out of the 48 DNA samples were also
analyzed by Monogram Biosciences Inc. using a commercial assay
developed by LabCorp Inc. The results were concordant for 23
out of 24 samples analyzed (Table S3). The discordant sample
(Coriell identifier NA18502) was a C/T heterozygote in both the
Sanger sequencing and TaqMan assays, but called a T/T
homozygote in the LabCorp assay. This sample was one of the
two HapMap samples with missing data.
To confirm that there had been no sample mix-up with
NA18502 in the author’s lab, a total of 8 SNPs from 4
chromosomes were determined in addition to a gender marker.
All 9 markers were fully concordant with HapMap data suggesting
that there was ,1% chance of a sample mix up (Table S4).
Upon further analysis at Monogram Biosciences Inc., the T/T
signals obtained for sample NA18502 were found to be
inconsistent with the normal distribution of T/T results observed
in the assay. The interpretation algorithm now used at Monogram
Figure 2. Sequence alignments surrounding six of the treatment response associated SNPs. Alignment comparing 50 bp sequence
surrounding SNP locations in IL28B reference sequence from NCBI genome build 37 and the corresponding reverse complement regions of IL28A
reference sequence (RC ref). SNP identifiers (color coded to match Figure 1) and their respective alleles are shown. Ancestral alleles were obtained
from dbSNP, except for those indicated by +; in these cases, the allele was based upon alignment of gorilla, chimpanzee, macaque and orangutan
sequences. SNP locations on each alignment are highlighted in red. The asterisk denotes sequence identity.
doi:10.1371/journal.pone.0029983.g002
Table 3. Allele frequencies of SNPs unique to IL28B region.
SNP rs12980275 rs8099917 rs7248668
Alleles A/G T/G G/A
Freq - CEU 0.56/0.44 0.75/0.25 0.75/0.25
Freq - JPT 0.91/0.09 0.91/0.09 0.91/0.09
Freq - YRI 0.47/0.53 0.97/0.03 0.97/0.03
doi:10.1371/journal.pone.0029983.t003
IL28 Polymorphism Sequencing and rs12979860 Assay
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result.
The Coriell Institute DNA samples are publically available,
therefore the same samples could be used in the future to
benchmark newly developed assays.
Discussion
Genome-wide association studies have demonstrated that SNPs
found in the region surrounding IL28B were associated with
response of patients infected with HCV to treatment with
pegylated interferon-a (with or without ribavirin) [4–6] and with
spontaneous clearance of HCV infection [7]. Over the last two
years, the number of publications examining IL28B SNPs has
increased tremendously and treatment options based upon a
patient’s IL28B SNP genotype are being considered [8,9].
The IL28B gene has a close paralogue, IL28A, with which it
shares 97.5% sequence identity. This raised the possibility that
sequences in IL28A may contribute to the determination of IL28B
SNP genotypes. Therefore, understanding genotype assay speci-
ficity would be vitally important to consider when using IL28B
genotypes to make treatment decisions. Clinicians need to be
confident that ‘homebrew’ assays are robust and fully validated to
allow prospective genotyping to make treatment decisions on
Table 4. Allele frequencies of IL28B SNPs and corresponding regions of IL28A.
SNP in IL28B region
SNP rs8105790 rs11881222 rs8103142 rs28416813 rs4803219 rs12979860
Alleles T/C A/G T/C C/G C/T C/T
Freq - CEU 0.75/0.25 0.59/0.41 0.56/0.44 0.63/0.37 0.66/0.34 0.53/0.47
Freq - JPT 0.91/0.09 0.91/0.09 0.91/0.09 0.91/0.09 0.91/0.09 0.91/0.09
Freq - YRI 0.78/0.22 0.69/0.31 0.31/0.69 0.34/0.66 0.66/0.34 0.34/0.66
Corresponding base in IL28A (reverse complement) sequence overlapping IL28B
rs8105790 rs11881222 rs8103142 rs28416813 rs4803219 rs12979860
Alleles CG CG CT
Freq - CEU 1.00 1.00 1.00 1.00 1.00 1.00
Freq - JPT 1.00 1.00 1.00 1.00 1.00 1.00
Freq - YRI 1.00 1.00 1.00 1.00 1.00 1.00
doi:10.1371/journal.pone.0029983.t004
Figure 3. Sequence alignment of IL28B and IL28A used to design the rs12979860 genotyping assay. Clustal W alignment of a portion of
the IL28B gene surrounding rs12979860 to the reverse complement (RC) of the corresponding region in IL28A. Locations of the genotyping assay
primers are shaded and the rs12979860 SNP is boxed and highlighted in red.
doi:10.1371/journal.pone.0029983.g003
IL28 Polymorphism Sequencing and rs12979860 Assay
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analyses.
The IL28A and IL28B genes likely arose due to an ancestral
gene duplication and inversion event, with IL28A being located on
the positive DNA strand of chromosome 19 and IL28B 24 kb
downstream on the negative strand. Although these genes are
97.5% identical across their 1.4 kb length, a region of .95%
sequence identity stretches a total of 7.3 kb in both 59 and 39
directions and it includes 6 of the 9 reported treatment response
associated SNPs. Our observation that in all cases, one of the two
alleles of the IL28B SNPs also corresponded to identical
nucleotides in IL28A led us to take a sequence-based approach
Figure 4. Allelic discrimination plot for the rs12979860 genotyping assay. Allelic discrimination plot generated by the SDS 2.3 software
(Applied Biosystems Inc.) for the rs12979860 genotyping assay using the 48 sample DNA panel. Red and blue circles represent the two homozygous
genotypes (T/T and C/C), the green circles represent heterozygous genotype (C/T) and the black squares represent no template control.
doi:10.1371/journal.pone.0029983.g004
IL28 Polymorphism Sequencing and rs12979860 Assay
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from a panel of DNA samples from 48 individuals representing
CEU, JPT and YRI origins demonstrated that all 9 SNPs in the
IL28B region were polymorphic, whereas the corresponding
sequences in IL28A were all monomorphic. Despite this finding,
there was still the potential for IL28A sequences to contribute to
genotyping calls if assays were not sufficiently specific.
As a general rule when developing PCR-based genotyping
assays, the greater the number of mismatches between the target
primers and other homologous sequences, the greater the assay
specificity. SNP rs12979860 currently appears to be the best single
choice variant for diagnostic purposes across global populations or
for use in clinical trials [8] and as a result, it has now become the
most studied SNP of the 9 treatment response associated SNPs
that were initially identified. Our TaqManH assay for rs12979860
used two PCR primers that contained 3 and 4 base mismatches
per primer compared to the corresponding IL28A sequences. This
assay gave 100% concordant results to the sequence-derived
genotypes. Whilst not implying that published rs12979860 assays
have not been technically validated, examining a selection of
different types of rs12979860 genotyping assays found varying
numbers of base mismatches in the PCR amplification primers.
For example, one TaqManH assay had 0 and 3 mismatches in the
amplification primer pairs [13,14], a PCR/Sybr green assay had 0
and 2 mismatches [15], and a MELT-MAMA PCR assay had 0
and 5 mismatches [16]. In these three examples, the specificity for
IL28B is only driven by a single primer. Two commercially
available rs12979860 assays from LabCorp Inc and Quest
Diagnostics Inc. have not reported details of their respective assay
components. Analysis of a 24 sample subset of the 48 Coriell
DNAs revealed one discordant genotype using the LabCorp assay;
interestingly in a sample that had its genotype missing in the
HapMap data. Re-analysis of this discordant data-point led to a
modification of the genotype calling algorithm now used at
Monogram Biosciences Inc.
Given the importance of the studies being used worldwide to
examine associations between SNP rs12979860 and response to
treatment in various hepatitis populations, it is vitally important
that robust and well validated assays are used. This is particularly
important as future hepatitis patient treatment decisions will likely
be dependent upon results obtained from such genotyping assays.
Supporting Information
Figure S1 Representative sequencing chromatograms
covering the 9 IL28B SNPs as well as the corresponding
regions in IL28A. Sanger sequencing chromatograms illustrat-
ing the different genotypes found in different Coriell samples for
each IL28B SNP and the corresponding regions in IL28A.
(DOC)
Figure S2 Sequencing chromatograms covering the
IL28B rs12979860 SNP for the 48 Coriell Institute DNA
sample panel. Sanger sequence chromatograms for the CEU
sample panel (NA17233 - NA17297), the JPT sample panel
(NA18954 -NA19085) and the YRI sample panel (NA18502 -
NA19223).
(DOC)
Table S1 Primers used to sequence PCR amplicons.
Details of sequencing primers used to examine the PCR amplicons
encompassing SNP locations in IL28B and the corresponding
reverse complement (RC) regions of IL28A.
(DOC)
Table S2 Novel SNPs identified in IL28A and IL28B gene
regions in DNA samples from the Coriell Institute. SNP
location and corresponding alleles are indicated using the IUPAC
ambiguity codes (R, S, W, Y).
(DOCX)
Table S3 Genotypes determined for Coriell Institute
DNA samples using DNA sequencing, TaqManH and
LabCorp genotyping assays and data extraction from
HapMap. Sample NA18502 (bold) is the sample with the
discordant result in the LabCorp Inc. assay. n/n indicates the 2
samples that were genotyped in HapMap project, but no results
were reported.
(DOCX)
Table S4 Concordance of additional genotypes deter-
mined for Coriell Institute DNA sample NA18502
compared to HapMap data (Release 24). r
2 values from
linkage disequilibrium analysis in the YRI population were 0.12
for rs2032586 and rs2235015 on chromosome 6; on chromosome
7 they were 0.06 for rs622342 and rs316019; and on chromosome
19 they were 0.48 for rs8105790 and rs11881222; 0.08 for
rs8105790 and rs7248668; and 0.05 for rs11881222 and
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